IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1640
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.8B
Yue H. Lin
Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BLTE BELITE BIO, INC | 52 | 24 | 43 | 90 | - | - | -99.2% | -95.0% | - | - | - | - | 0.0% | 0.0x | $1.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
BELITE BIO, INC (BLTE) receives a "Hold" rating with a composite score of 52.3/100. It ranks #1640 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for BLTE.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 24 | 7 | +17ALPHA |
| MOMENTUM | 90 | 95 | -5NEUTRAL |
| VALUATION | 43 | 32 | +11ALPHA |
| INVESTMENT | 18 | 1 | +17ALPHA |
| STABILITY | 74 | 77 | -3NEUTRAL |
| SHORT INT | 37 | 30 | +7ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -99.2% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 3yr history
Interest coverage -1999.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate BELITE BIO, INC (BLTE) as a Hold with a composite score of 52.3/100 at a current price of $189.84. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
BELITE BIO, INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.3/100 places it at rank #1640 in our full universe.
No Moat
Low
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
BELITE BIO, INC represents a hold based on multi-factor quantitative performance.
Our model assigns BELITE BIO, INC a Hold rating, with a composite score of 52.3/100 and 3 out of 5 stars. Ranked #1640 of 7,333 stocks, BLTE presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
BELITE BIO, INC registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -99.2% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 43/100, BLTE appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 46.55x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
BELITE BIO, INC's investment score of 18/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -95.0% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
BELITE BIO, INC (BLTE) is exhibiting exceptional momentum with a score of 90/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of 0.70 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting BLTE may continue to benefit from strong institutional interest and positive price trends.
BLTE shows good financial stability with a score of 74/100. Key stability metrics include a beta of 0.70 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
BELITE BIO, INC's short interest score of 37/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include small-cap liquidity risk. At $1.8B (small-cap), BLTE carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
BELITE BIO, INC is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1640 of 7,333 overall (78th percentile). Key comparisons include ROE of -99.2% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BLTE currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (90) vs Investment (18) — closing this gap could shift the rating.
ROE 5118% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025. Webcast InformationDate: Mo
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong. The presentations will include previously disclosed to
Belite Bio (BLTE) has been attracting attention after recent share price moves, with the stock closing at US$189.26 and showing strong returns over the past month and past 3 months. See our latest analysis for Belite Bio. Beyond the recent move, Belite Bio’s 30 day share price return of 15.00% and 90 day share price return of 48.09%, alongside a very large 3 year total shareholder return, point to momentum that has built over time as investors reassess growth potential and risk around its...
Belite Bio (BLTE) completed enrollment of 60 adolescents in its global Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a key clinical milestone that investors often watch closely. See our latest analysis for Belite Bio. The latest clinical milestone comes on top of a strong run in the shares, with Belite Bio’s 30 day share price return of 18.63% and 90 day share price return of 77.63%. Its 1 year total shareholder return of 249.18% and 3 year total shareholder...
Belite Bio (BLTE) is back in focus after confirming it will present topline Phase 3 DRAGON data for tinlarebant in adolescent Stargardt disease at the upcoming Asia Pacific Academy of Ophthalmology Congress. See our latest analysis for Belite Bio. Those DRAGON data presentations come after a strong run in the stock, with a 90 day share price return of 50.36% and a 1 year total shareholder return of 191.18%, suggesting momentum has been building around the story. If you are watching how...